December 15, 2015

Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone EF-14 trial results supported recent FDA approval of Optune for newly diagnosed GBM December 15, 2015 11:01 AM Eastern Standard Time… Read More
learn more
December 15, 2015

Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data

December 15, 2015 11:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the American Medical Association (JAMA). Read More
learn more
December 14, 2015

New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells December 14, 2015 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–New preclinical data on Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy revealed a more thorough… Read More
learn more
December 3, 2015

Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts

Removal of FDA contraindication increases addressable GBM patient population December 03, 2015 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–A retrospective analysis of Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult glioblastoma patients with implanted non-programmable… Read More
learn more
December 2, 2015

Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer

December 02, 2015 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure (NASDAQ: NVCR), show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung… Read More
learn more